Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 15, 2022
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 10, 2020
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 14, 2019
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Journal: Cancer chemotherapy and pharmacology
Published: January 09, 2018
Showing 1-5 of 5
Last Updated: 09/26/2026